Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.
KIRhub 2.0· v2
Ependymoma Hub
V1V2
Sign in
← Cases

Capmatinib

83a78653-c635-592d-ae54-eeb754cc4c2b · FDA Approved · targets C_MET

Capmatinib

MeasuredReference

Capmatinib targets C_MET. Strongest hallmark effect: tumor promoting inflammation.

Primary targets

C_MET

Top hallmarks

  • tumor promoting inflammation1.3k
  • proliferation1.1k
  • evading apoptosis1.1k

Top pathways disrupted

No pathway data.

Resistance landscape — Capmatinib

MeasuredReference

10 known oncogenic variants exist on Capmatinib's top targets — see detail for inhibition impact.

Open in new tab